Multiple Sclerosis Drugs Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Multiple Sclerosis Drugs Market: By Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), BY Drug Class (Disease Modifying Drugs (DMDs), Steroids, Others), and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

Multiple Sclerosis Drugs Market size was valued at USD 23.43 billion in 2021 and is poised to grow at a CAGR of 4.0% over the forecast period 2022-28. Multiple Sclerosis Drugs Market: Multiple Sclerosis (MS) is a demyelinating disease that affects spinal cord and brain. Multiple sclerosis damages myelin sheath, material that surrounds and protects nerve cells. This damage blocks or slows down messages between brain and body. The exact cause of the Multiple Sclerosis disease is unknown but it is an autoimmune disease diagnosis. Some of the major problems include doubled vision, psychological, mental disturbances and not having coordination in body movements. Most of the people diagnosed with MS are between the age 20 to 50 years and it can occur in young children and significantly older adults. The unmet need of drugs for the treatment of multiple sclerosis, extensive R&D pipelines and prevalence of the disease are driving factors for the market growth of Multiple Sclerosis drug market. According to the Atlas MS, there are about 2.3 million people are with multiple sclerosis, and most of the patients are not diagnosed with multiple sclerosis and certain parts of the world due to the lacking of healthcare infrastructure and unawareness. The advancements in the biomedical science about to create a profitable opportunities for multiple sclerosis drug makers in near future. However patent expiry of the key drugs is key restraint for multiple sclerosis market, In addition strengthening of regulatory requirements and procedures also making difficulties in steady market growth. The global multiple sclerosis drugs market is majorly influenced by increased number of patients from secondary progressive relapsing-remitting multiple sclerosis. The awareness in identifying multiple sclerosis disease conditions increased because of organizations such as National MS society and Multiple Sclerosis Association of America (MSAA) are actively involved in educating the people regarding associated symptoms and increasing the awareness. The presence of strong pipeline drugs such as pleneva (BTG international Ltd.), cladribine (Merck &Co., Inc) and their expected commercialization witness to boost the market share. Companies also actively involved in collaborating with other drug manufacturers for development of drugs such as ampryra (Acordda Therapeutics and Biogen Idec), laquinimod (Active Biotech and Teva Pharmaceuticals), and rebif (Merck Serono and Pfizer). These initiatives are enabling the manufactures to strengthen their product share in Multiple sclerosis drug market. In Multiple sclerosis drug market segments immunomodulators are predominantly used compared to othersegments. On the arrival of the easier-to-use oral drugs, market share of the injectables has decreased.

Multiple Sclerosis Drugs Market

MARKET SUMMARY
-
4.0% CAGR
  • Study Period– 2022-2028
  • Base Year– 2021
  • CAGR– 4.0%
  • Largest Market– North America
  • Fastest Growing Market– Asia Pacific

Multiple Sclerosis Drugs Market

  • The report on global multiple sclerosis drugs market gives historical, current, and future market sizes (US$ Mn) on the basis of administration, distribution channel, drug class and geography.
  • The multiple sclerosis drugs market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa
Key Players
  • Novartis AG (Switzerland)
  • Teva Pharmaceutical industries Ltd. (Israel)
  • Biogen, Inc. (U.S.)
  • Merck & Co., Inc. (U.S.)
  • Sanofi (France)
Multiple Sclerosis Drugs Market Dynamics

The global multiple sclerosis drugs market is majorly influenced by increased number of patients from secondary progressive relapsing-remitting multiple sclerosis. The awareness in identifying multiple sclerosis disease conditions increased because of organizations such as National MS society and Multiple Sclerosis Association of America (MSAA) are actively involved in educating the people regarding associated symptoms and increasing the awareness.


North-America Got Significant Share

Multiple Sclerosis Drugs Market

Geographically multiple sclerosis drug market segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Among these regions North America is more dominating in Multiple sclerosis drug market. Multiple sclerosis related healthcare estimated more than $10bn in U.S. In North America, U.S. dominates overall market and followed by Canada. In Europe countries like Italy, Spain, and the UK holds the major share due to increased prevalence rate of multiple sclerosis. In Asian pacific region developing countries like regions like India China have advantage for the drug makers over the developed markets due to low cost of production and high availability of talent pool. Because most of the multiple sclerosis drug are biomedical drugs and requires more investment and time for developing biological products.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2015-2020) and forecast (2021-2027)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Multiple Sclerosis Drugs Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content

  1. Executive summary
  2. Global Multiple Sclerosis Drugs Market Introduction
    • Global Multiple Sclerosis Drugs Market – Taxonomy
    • Global Multiple Sclerosis Drugs Market –Definitions
      • Drug Class
      • Distribution Channel
  1. Global Multiple Sclerosis Drugs Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global Multiple Sclerosis Drugs Market Dynamics – Factors Impact Analysis
    • Global Multiple Sclerosis Drugs Market – Regulations
      • US
      • Europe
      • Japan
    • Global Multiple Sclerosis Drugs Market – Recent Product Launches
  2. Global Multiple Sclerosis Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market Oppurtunity Analysis
  3. Global Multiple Sclerosis Drugs Market, By Drug Class, 2013 – 2017 and Forecast, 2018 – 2024
    • Disease Modifying Drugs (DMDs)
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Steroids
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Multiple Sclerosis Drugs Market, By Route of Administration, 2013 – 2017 and Forecast, 2018 – 2024
    • Oral
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Parenteral
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Multiple Sclerosis Drugs Market Forecast, By Distribution Channel, 2013 – 2017 and Forecast, 2018 – 2024
    • Hospital Pharmacies
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Retail Pharmacies
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Online Pharmacies
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Multiple Sclerosis Drugs Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024
    • North America
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global Multiple Sclerosis Drugs Market – Opportunity Analysis Index – By Drug Class, By Route of Administration, By Distribution Channel, and Region, 2018 – 2024
  2. North America Multiple Sclerosis Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Disease Modifying Drugs (DMDs)
      • Steroids
      • Others
    • Route of Administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Retail Pharmacies
      • Hospital Pharmacies
      • Online Pharmacies
    • Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • US
      • Canada
    • North America Multiple Sclerosis Drugs Market – Opportunity Analysis Index – By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
    • North America Multiple Sclerosis Drugs Market Dynamics – Trends
  3. Europe Multiple Sclerosis Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Disease Modifying Drugs (DMDs)
      • Steroids
      • Others
    • Route of Administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Retail Pharmacies
      • Hospital Pharmacies
      • Online Pharmacies
    • Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe Multiple Sclerosis Drugs Market – Opportunity Analysis Index – By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
    • Europe Multiple Sclerosis Drugs Market Dynamics – Trends
  4. Asia-Pacific Multiple Sclerosis Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Disease Modifying Drugs (DMDs)
      • Steroids
      • Others
    • Route of Administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Retail Pharmacies
      • Hospital Pharmacies
      • Online Pharmacies
    • Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn),
  5. Y-o-Y Growth (%), and Market Share (%)
    • Japan
    • China
    • India
    • ASEAN
    • Australia & New Zealand
    • Rest of Asia-Pacific
  • Asia-Pacific Multiple Sclerosis Drugs Market – Opportunity Analysis Index – By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
  • Asia-Pacific Multiple Sclerosis Drugs Market Dynamics – Trends
  1. Latin America Multiple Sclerosis Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Disease Modifying Drugs (DMDs)
      • Steroids
      • Others
    • Route of Administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Retail Pharmacies
      • Hospital Pharmacies
      • Online Pharmacies
    • Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Venezuela
      • Rest of Latin America
    • Latin America Multiple Sclerosis Drugs Market – Opportunity Analysis Index – By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
    • Latin America Multiple Sclerosis Drugs Market Dynamics – Trends
  2. Middle East & Africa Multiple Sclerosis Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Disease Modifying Drugs (DMDs)
      • Steroids
      • Others
    • Route of Administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Retail Pharmacies
      • Hospital Pharmacies
      • Online Pharmacies
    • Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA Multiple Sclerosis Drugs Market – Opportunity Analysis Index – By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
    • MEA Multiple Sclerosis Drugs Market Dynamics – Trends
  3. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • Novartis AG (Switzerland)
      • Teva Pharmaceutical industries Ltd. (Israel)
      • Biogen, Inc. (U.S.)
      • Merck & Co., Inc. (U.S.)
      • Sanofi S.A. (France)
      • Acorda Therapeuitics (U.S.)
      • Pfizer Inc. (U.S.)
      • Bayer AG (Germany)
      • Medtronic plc (Questcor Pharmaceuiticals) (U.S.)
  1. Research Methodology
  2. Key Assumptions and Acronyms

Report

Company Profile

  • Novartis AG (Switzerland)
  • Teva Pharmaceutical industries Ltd. (Israel)
  • Biogen, Inc. (U.S.)
  • Merck & Co., Inc. (U.S.)
  • Sanofi (France)
  • Acorda Therapeuitics (U.S.)
  • Pfizer Inc. (U.S.)
  • Bayer AG (Germany)
  • Medtronic plc (Questcor Pharmaceuiticals) (U.S.)

Description

Multiple Sclerosis Drugs Market size was valued at USD 23.43 billion in 2021 and is poised to grow at a CAGR of 4.0% over the forecast period 2022-28. Multiple Sclerosis Drugs Market: Multiple Sclerosis (MS) is a demyelinating disease that affects spinal cord and brain. Multiple sclerosis damages myelin sheath, material that surrounds and protects nerve cells. This damage blocks or slows down messages between brain and body. The exact cause of the Multiple Sclerosis disease is unknown but it is an autoimmune disease diagnosis. Some of the major problems include doubled vision, psychological, mental disturbances and not having coordination in body movements. Most of the people diagnosed with MS are between the age 20 to 50 years and it can occur in young children and significantly older adults. The unmet need of drugs for the treatment of multiple sclerosis, extensive R&D pipelines and prevalence of the disease are driving factors for the market growth of Multiple Sclerosis drug market. According to the Atlas MS, there are about 2.3 million people are with multiple sclerosis, and most of the patients are not diagnosed with multiple sclerosis and certain parts of the world due to the lacking of healthcare infrastructure and unawareness. The advancements in the biomedical science about to create a profitable opportunities for multiple sclerosis drug makers in near future. However patent expiry of the key drugs is key restraint for multiple sclerosis market, In addition strengthening of regulatory requirements and procedures also making difficulties in steady market growth. The global multiple sclerosis drugs market is majorly influenced by increased number of patients from secondary progressive relapsing-remitting multiple sclerosis. The awareness in identifying multiple sclerosis disease conditions increased because of organizations such as National MS society and Multiple Sclerosis Association of America (MSAA) are actively involved in educating the people regarding associated symptoms and increasing the awareness. The presence of strong pipeline drugs such as pleneva (BTG international Ltd.), cladribine (Merck &Co., Inc) and their expected commercialization witness to boost the market share. Companies also actively involved in collaborating with other drug manufacturers for development of drugs such as ampryra (Acordda Therapeutics and Biogen Idec), laquinimod (Active Biotech and Teva Pharmaceuticals), and rebif (Merck Serono and Pfizer). These initiatives are enabling the manufactures to strengthen their product share in Multiple sclerosis drug market. In Multiple sclerosis drug market segments immunomodulators are predominantly used compared to othersegments. On the arrival of the easier-to-use oral drugs, market share of the injectables has decreased.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX